GLMD (Galmed Pharmaceuticals) Margin resik

Clinical delay risks and pressure to expand the portfolio are creating a financial burden for Galmed Pharmaceuticals (GLMD). Net profit margins on shipments visualize these challenges, where 0.00 is the current value of the indicator. Meanwhile, authority in orphan disease therapy and the safety of Aramchol sustain confidence, while the focus on treating fatty liver disease unlocks significant market potential.
Galmed Pharmaceuticals Ltd. (GLMD) - rincian metrik lan laporan keuangan

This indicator determines the investment reliability of the issuer through its ability to generate profit. The metric is calculated as the ratio of net income to total revenue, measuring cost management efficiency. An analysis of net profit margin allows for an assessment of the business's resilience to external shocks. The net profit margin trend confirms that margins are protected by patents for synthetic fatty acids. Stringent FDA requirements create barriers, guaranteeing Galmed Pharmaceuticals (GLMD) a long-term competitive advantage.